FC
BIO icon

Farringdon Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Farringdon Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,379
Closed -$667K – 456
2025
Q3 		$667K Buy
+2,379
New +$647K 0.17% 182

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Farringdon Capital's BIO Position: Q4 2025 in Review

Farringdon Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 2,379 shares — an estimated $667K sold.

Farringdon Capital first reported a position in BIO in Q3 2025 and held it in 1 quarter. The position peaked at $667K in Q3 2025. 396 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

  • Farringdon Capital reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
  • Farringdon Capital sold 2,379 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $667K.
  • Farringdon Capital first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and held it in 1 quarter.
  • Farringdon Capital's Bio-Rad Laboratories Class A position peaked at $667K in Q3 2025.
  • 396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Farringdon Capital's 13F filing for Q4 2025, filed 17 Feb 2026.